Phase I and pharmacokinetic study of etoposide phosphate

D. J. Brooks, N. R. Srinivas, David S Alberts, T. Thomas, L. M. Igwemzie, L. M. McKinney, J. Randolph, L. Schacter, S. Kaul, R. H. Barbhaiya

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which Is useful In the treatment of a wide variety of hematological malignancies and solid tumors. Because etoposide Is poorly water soluble, it must be dissolved in a variety of organic solvents and given in relatively large volumes of saline. EP is rapidly converted to the parent drug in vivo and has been shown to be active in animal studies. We performed a phase I pharmacokinetic study in 27 patients. Three patients each received an etoposide-equivalent dose of 50 or 75 mg/m2 each day by i.v. bolus (5 min) daily for 5 days and 21 patients received a dose equivalent to 100 mg/m2 of etoposide each day for 5 days. Non-compartmental pharmacokinetic data were obtained for 22 of the patients. As with previous studies, EP behaves as a prodrug of etoposide. The C(max) (25.3-42.5 μg/ml increased linearly, while AUC(inf) (75.8-156 h μg/ml) of etoposide increased proportionately with dose (50-100 mg/m2 of etoposide equivalents). Time to achieve C(max) corresponded to the end of the 5 min injection, indicating a rapid formation of etoposide from EP. Mean etoposide phosphate/etoposide C(max) and AUC(inf) ratios were 0.08 or less and 0.003, respectively, indicating that the major circulating moiety in plasma was etoposide. Parameters such as MRT, T( 1/2 ), CL/F, CL(R), V(ss)/F and %UR were dose independent. The toxicities of EP were virtually identical to those seen with etoposide, with dose-related myelosuppression, alopecia and stomatitis. Severe neutropenia was the dose-limiting toxicity. No significant problems with hypotension or allergic reactions were observed. No problems, difficulties or complications were observed as a result of bolus (5 min) administration. On the basis of phase I toxicity data, we recommend an etoposide equivalent starting dose of 100 mg/m2/day for 5 days in previously untreated patients who have an excellent performance status. In patients who have had one or more prior chemotherapy regimens, extensive prior radiation therapy or moderately impaired performance status, we recommend an etoposide phosphate starting dose of 75 mg/m2/day for 5 days with courses repeated at 3 week intervals.

Original languageEnglish (US)
Pages (from-to)637-644
Number of pages8
JournalAnti-Cancer Drugs
Volume6
Issue number5
StatePublished - 1995

Fingerprint

Etoposide
Pharmacokinetics
etoposide phosphate
Area Under Curve
Podophyllotoxin
Stomatitis
Water
Alopecia
Prodrugs
Hematologic Neoplasms
Neutropenia
Hypotension
Hypersensitivity
Radiotherapy
Parents

Keywords

  • Etoposide phosphate
  • Pharmacokinetics
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Brooks, D. J., Srinivas, N. R., Alberts, D. S., Thomas, T., Igwemzie, L. M., McKinney, L. M., ... Barbhaiya, R. H. (1995). Phase I and pharmacokinetic study of etoposide phosphate. Anti-Cancer Drugs, 6(5), 637-644.

Phase I and pharmacokinetic study of etoposide phosphate. / Brooks, D. J.; Srinivas, N. R.; Alberts, David S; Thomas, T.; Igwemzie, L. M.; McKinney, L. M.; Randolph, J.; Schacter, L.; Kaul, S.; Barbhaiya, R. H.

In: Anti-Cancer Drugs, Vol. 6, No. 5, 1995, p. 637-644.

Research output: Contribution to journalArticle

Brooks, DJ, Srinivas, NR, Alberts, DS, Thomas, T, Igwemzie, LM, McKinney, LM, Randolph, J, Schacter, L, Kaul, S & Barbhaiya, RH 1995, 'Phase I and pharmacokinetic study of etoposide phosphate', Anti-Cancer Drugs, vol. 6, no. 5, pp. 637-644.
Brooks DJ, Srinivas NR, Alberts DS, Thomas T, Igwemzie LM, McKinney LM et al. Phase I and pharmacokinetic study of etoposide phosphate. Anti-Cancer Drugs. 1995;6(5):637-644.
Brooks, D. J. ; Srinivas, N. R. ; Alberts, David S ; Thomas, T. ; Igwemzie, L. M. ; McKinney, L. M. ; Randolph, J. ; Schacter, L. ; Kaul, S. ; Barbhaiya, R. H. / Phase I and pharmacokinetic study of etoposide phosphate. In: Anti-Cancer Drugs. 1995 ; Vol. 6, No. 5. pp. 637-644.
@article{b889d6d049694241a927ff4d6fde3448,
title = "Phase I and pharmacokinetic study of etoposide phosphate",
abstract = "Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which Is useful In the treatment of a wide variety of hematological malignancies and solid tumors. Because etoposide Is poorly water soluble, it must be dissolved in a variety of organic solvents and given in relatively large volumes of saline. EP is rapidly converted to the parent drug in vivo and has been shown to be active in animal studies. We performed a phase I pharmacokinetic study in 27 patients. Three patients each received an etoposide-equivalent dose of 50 or 75 mg/m2 each day by i.v. bolus (5 min) daily for 5 days and 21 patients received a dose equivalent to 100 mg/m2 of etoposide each day for 5 days. Non-compartmental pharmacokinetic data were obtained for 22 of the patients. As with previous studies, EP behaves as a prodrug of etoposide. The C(max) (25.3-42.5 μg/ml increased linearly, while AUC(inf) (75.8-156 h μg/ml) of etoposide increased proportionately with dose (50-100 mg/m2 of etoposide equivalents). Time to achieve C(max) corresponded to the end of the 5 min injection, indicating a rapid formation of etoposide from EP. Mean etoposide phosphate/etoposide C(max) and AUC(inf) ratios were 0.08 or less and 0.003, respectively, indicating that the major circulating moiety in plasma was etoposide. Parameters such as MRT, T( 1/2 ), CL/F, CL(R), V(ss)/F and {\%}UR were dose independent. The toxicities of EP were virtually identical to those seen with etoposide, with dose-related myelosuppression, alopecia and stomatitis. Severe neutropenia was the dose-limiting toxicity. No significant problems with hypotension or allergic reactions were observed. No problems, difficulties or complications were observed as a result of bolus (5 min) administration. On the basis of phase I toxicity data, we recommend an etoposide equivalent starting dose of 100 mg/m2/day for 5 days in previously untreated patients who have an excellent performance status. In patients who have had one or more prior chemotherapy regimens, extensive prior radiation therapy or moderately impaired performance status, we recommend an etoposide phosphate starting dose of 75 mg/m2/day for 5 days with courses repeated at 3 week intervals.",
keywords = "Etoposide phosphate, Pharmacokinetics, Phase I",
author = "Brooks, {D. J.} and Srinivas, {N. R.} and Alberts, {David S} and T. Thomas and Igwemzie, {L. M.} and McKinney, {L. M.} and J. Randolph and L. Schacter and S. Kaul and Barbhaiya, {R. H.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "637--644",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase I and pharmacokinetic study of etoposide phosphate

AU - Brooks, D. J.

AU - Srinivas, N. R.

AU - Alberts, David S

AU - Thomas, T.

AU - Igwemzie, L. M.

AU - McKinney, L. M.

AU - Randolph, J.

AU - Schacter, L.

AU - Kaul, S.

AU - Barbhaiya, R. H.

PY - 1995

Y1 - 1995

N2 - Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which Is useful In the treatment of a wide variety of hematological malignancies and solid tumors. Because etoposide Is poorly water soluble, it must be dissolved in a variety of organic solvents and given in relatively large volumes of saline. EP is rapidly converted to the parent drug in vivo and has been shown to be active in animal studies. We performed a phase I pharmacokinetic study in 27 patients. Three patients each received an etoposide-equivalent dose of 50 or 75 mg/m2 each day by i.v. bolus (5 min) daily for 5 days and 21 patients received a dose equivalent to 100 mg/m2 of etoposide each day for 5 days. Non-compartmental pharmacokinetic data were obtained for 22 of the patients. As with previous studies, EP behaves as a prodrug of etoposide. The C(max) (25.3-42.5 μg/ml increased linearly, while AUC(inf) (75.8-156 h μg/ml) of etoposide increased proportionately with dose (50-100 mg/m2 of etoposide equivalents). Time to achieve C(max) corresponded to the end of the 5 min injection, indicating a rapid formation of etoposide from EP. Mean etoposide phosphate/etoposide C(max) and AUC(inf) ratios were 0.08 or less and 0.003, respectively, indicating that the major circulating moiety in plasma was etoposide. Parameters such as MRT, T( 1/2 ), CL/F, CL(R), V(ss)/F and %UR were dose independent. The toxicities of EP were virtually identical to those seen with etoposide, with dose-related myelosuppression, alopecia and stomatitis. Severe neutropenia was the dose-limiting toxicity. No significant problems with hypotension or allergic reactions were observed. No problems, difficulties or complications were observed as a result of bolus (5 min) administration. On the basis of phase I toxicity data, we recommend an etoposide equivalent starting dose of 100 mg/m2/day for 5 days in previously untreated patients who have an excellent performance status. In patients who have had one or more prior chemotherapy regimens, extensive prior radiation therapy or moderately impaired performance status, we recommend an etoposide phosphate starting dose of 75 mg/m2/day for 5 days with courses repeated at 3 week intervals.

AB - Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which Is useful In the treatment of a wide variety of hematological malignancies and solid tumors. Because etoposide Is poorly water soluble, it must be dissolved in a variety of organic solvents and given in relatively large volumes of saline. EP is rapidly converted to the parent drug in vivo and has been shown to be active in animal studies. We performed a phase I pharmacokinetic study in 27 patients. Three patients each received an etoposide-equivalent dose of 50 or 75 mg/m2 each day by i.v. bolus (5 min) daily for 5 days and 21 patients received a dose equivalent to 100 mg/m2 of etoposide each day for 5 days. Non-compartmental pharmacokinetic data were obtained for 22 of the patients. As with previous studies, EP behaves as a prodrug of etoposide. The C(max) (25.3-42.5 μg/ml increased linearly, while AUC(inf) (75.8-156 h μg/ml) of etoposide increased proportionately with dose (50-100 mg/m2 of etoposide equivalents). Time to achieve C(max) corresponded to the end of the 5 min injection, indicating a rapid formation of etoposide from EP. Mean etoposide phosphate/etoposide C(max) and AUC(inf) ratios were 0.08 or less and 0.003, respectively, indicating that the major circulating moiety in plasma was etoposide. Parameters such as MRT, T( 1/2 ), CL/F, CL(R), V(ss)/F and %UR were dose independent. The toxicities of EP were virtually identical to those seen with etoposide, with dose-related myelosuppression, alopecia and stomatitis. Severe neutropenia was the dose-limiting toxicity. No significant problems with hypotension or allergic reactions were observed. No problems, difficulties or complications were observed as a result of bolus (5 min) administration. On the basis of phase I toxicity data, we recommend an etoposide equivalent starting dose of 100 mg/m2/day for 5 days in previously untreated patients who have an excellent performance status. In patients who have had one or more prior chemotherapy regimens, extensive prior radiation therapy or moderately impaired performance status, we recommend an etoposide phosphate starting dose of 75 mg/m2/day for 5 days with courses repeated at 3 week intervals.

KW - Etoposide phosphate

KW - Pharmacokinetics

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0028786202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028786202&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 637

EP - 644

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -